Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

July 1, 2024

Study Completion Date

July 10, 2024

Conditions
Meniere Disease
Interventions
DEVICE

taVNS

TaVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients. Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms \[18,28\]. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. In the taVNS group received 12 weeks of treatment (30 min each time, once daily, 5 times per week).

DRUG

Betahistine Mesylate tablet

Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.

Trial Locations (1)

100730

China Beijing TongRen Hospital, Capital Medical University Beijing, China, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER

NCT06544590 - Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease | Biotech Hunter | Biotech Hunter